Chemotherapy strategies in the treatment of small cell lung cancer

被引：18

作者：

Popat, S

O'Brien, M

机构：

[1] Royal Marsden Hosp, Dept Med, Lung Unit, Sutton SM2 5PT, Surrey, England

[2] Inst Canc Res, Sect Canc Genet, Sutton, Surrey, England

来源：

ANTI-CANCER DRUGS | 2005年 / 16卷 / 04期

关键词：

chemotherapy; small cell lung cancer; treatment;

D O I：

10.1097/00001813-200504000-00002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Lung cancer is the most prevalent, yet most preventable malignancy worldwide. Given the tendency of small cell lung cancer (SCLC) to early relapse and its subsequent resistance to treatment, there is an urgent need to optimize standard treatment strategies and develop new treatments. Over the last decade, several strategies have been adopted and advances in the molecular biology of lung cancer have identified a number of targets for future therapy. In this article, we review chemotherapy strategies that have been evaluated in the management of patients with SCLC. (c) 2005 Lippincott Williams & Wilkins.

引用

页码：361 / 372

页数：12

共 100 条

[1] Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: A prospective European organization for research and treatment of cancer-lung cancer group phase III trial-08923 [J].

Ardizzoni, A ;

Tjan-Heijnen, VCG ;

Postmus, PE ;

Buchholz, E ;

Biesma, B ;

Karnicka-Mlodkowska, H ;

Dziadziuszko, R ;

Burghouts, J ;

van Meerbeeck, JP ;

Gans, S ;

Legrand, C ;

Debruyne, C ;

Giaccone, G ;

Manegold, C .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (19) :3947-3955

[2] Initial chemotherapeutic doses and long-term survival in limited small-cell lung cancer. [J].

Arriagada, R ;

Pignon, J ;

Le Chevalier, T .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (17) :1281-1282

[3] INITIAL CHEMOTHERAPEUTIC DOSES AND SURVIVAL IN PATIENTS WITH LIMITED SMALL-CELL LUNG-CANCER [J].

ARRIAGADA, R ;

LECHEVALIER, T ;

PIGNON, JP ;

RIVIERE, A ;

MONNET, I ;

CHOMY, P ;

TUCHAIS, C ;

TARAYRE, M ;

RUFFIE, P .

NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (25) :1848-1852

[4] A randomized pilot study of SRL172 (Mycobacterium vaccae) in patients with small cell lung cancer (SCLC) treated with chemotherapy [J].

Assersohn, L ;

Souberbielle, BE ;

O'Brien, MER ;

Archer, CD ;

Mendes, R ;

Bass, R ;

Bromelow, KV ;

Palmer, RD ;

Bouilloux, E ;

Kennard, DA ;

Smith, IE .

CLINICAL ONCOLOGY, 2002, 14 (01) :23-27

[5] Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission [J].

Aupérin, A ;

Arriagada, R ;

Pignon, JP ;

Le Péchoux, C ;

Gregor, A ;

Stephens, RJ ;

Kristjansen, PEG ;

Johnson, BE ;

Ueoka, H ;

Wagner, H ;

Aisner, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (07) :476-484

[6] A randomized trial of aspirin to prevent colorectal adenomas [J].

Baron, JA ;

Cole, BF ;

Sandler, RS ;

Haile, RW ;

Ahnen, D ;

Bresalier, R ;

McKeown-Eyssen, G ;

Summers, RW ;

Rothstein, R ;

Burke, CA ;

Snover, DC ;

Church, TR ;

Allen, JI ;

Beach, M ;

Beck, GJ ;

Bond, JH ;

Byers, T ;

Greenberg, ER ;

Mandel, JS ;

Marcon, N ;

Mott, LA ;

Pearson, L ;

Saibil, F ;

van Stolk, RU .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (10) :891-899

[7] Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent [J].

Bauer, KS ;

Dixon, SC ;

Figg, WD .

BIOCHEMICAL PHARMACOLOGY, 1998, 55 (11) :1827-1834

[8] Long-term follow-up of a randomised trial of combined chemoradiotherapy induction treatment, with and without maintenance chemotherapy in patients with small cell carcinoma of the lung [J].

Beith, JM ;

Clarke, SJ ;

Woods, RL ;

Bell, DR ;

Levi, JA .

EUROPEAN JOURNAL OF CANCER, 1996, 32A (03) :438-443

[9]

BLEEHEN NM, 1989, BRIT J CANCER, V59, P584

[10] A RANDOMIZED TRIAL OF 3 OR 6 COURSES OF ETOPOSIDE CYCLOPHOSPHAMIDE METHOTREXATE AND VINCRISTINE OR 6 COURSES OF ETOPOSIDE AND IFOSFAMIDE IN SMALL-CELL LUNG-CANCER (SCLC) .1. SURVIVAL AND PROGNOSTIC FACTORS [J].

BLEEHEN, NM ;

GIRLING, DJ ;

MACHIN, D ;

STEPHENS, RJ ;

BARLEY, VL ;

BULLIMORE, JA ;

WHITE, RJ ;

BLEEHAN, NM ;

WILLIAMS, MV ;

BREDIN, CP ;

DAVIDSON, AR ;

WILLIAMS, TJ ;

ASH, DV ;

CLOSE, HJ ;

JOSLIN, CA ;

MUERS, MF ;

STONE, J ;

ASHFORD, RF ;

DISCHE, S ;

DUNPHY, EP ;

FERMONT, DC ;

GROSCH, E ;

MAHER, EJ ;

SAUNDERS, MI ;

ADAM, RJ ;

ALCOCK, CJ ;

BENSON, MK ;

HOPKIN, JM ;

LANE, DJ ;

HUNTER, AM .

BRITISH JOURNAL OF CANCER, 1993, 68 (06) :1150-1156

← 1 2 3 4 5 6 7 8 9 10 →